JP2010071789A5 - - Google Patents

Download PDF

Info

Publication number
JP2010071789A5
JP2010071789A5 JP2008239303A JP2008239303A JP2010071789A5 JP 2010071789 A5 JP2010071789 A5 JP 2010071789A5 JP 2008239303 A JP2008239303 A JP 2008239303A JP 2008239303 A JP2008239303 A JP 2008239303A JP 2010071789 A5 JP2010071789 A5 JP 2010071789A5
Authority
JP
Japan
Prior art keywords
phase
patient
determining
peptide
remission
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008239303A
Other languages
Japanese (ja)
Other versions
JP2010071789A (en
JP5117336B2 (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2008239303A priority Critical patent/JP5117336B2/en
Priority claimed from JP2008239303A external-priority patent/JP5117336B2/en
Publication of JP2010071789A publication Critical patent/JP2010071789A/en
Publication of JP2010071789A5 publication Critical patent/JP2010071789A5/ja
Application granted granted Critical
Publication of JP5117336B2 publication Critical patent/JP5117336B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (9)

多発性硬化症またはＮＭＯ（視神経脊髄炎）患者由来の生体試料中の、配列番号１で表されるアミノ酸配列からなるペプチドの量を測定することを特徴とする、多発性硬化症またはＮＭＯの再発期と寛解期とを判定するためのペプチドマーカーの測定方法。   Recurrence of multiple sclerosis or NMO characterized by measuring the amount of a peptide comprising the amino acid sequence represented by SEQ ID NO: 1 in a biological sample derived from a patient with multiple sclerosis or NMO (optic neuromyelitis) A method for measuring a peptide marker for determining a period and a remission period. 生体試料が血液サンプルである、請求項１に記載の測定方法。   The measurement method according to claim 1, wherein the biological sample is a blood sample. 質量分析計によりペプチド値を測定する、請求項１または２に記載の測定方法。   The measurement method according to claim 1, wherein the peptide value is measured by a mass spectrometer. 質量分析計がレーザーイオン化飛行時間型質量分析計である、請求項３に記載の測定方法。   The measurement method according to claim 3, wherein the mass spectrometer is a laser ionization time-of-flight mass spectrometer. 血液中の配列番号１で表されるアミノ酸配列からなるペプチドの量を測定することを特徴とする、多発性硬化症の再発期と寛解期とを判定する、またはＮＭＯ（視神経脊髄炎）の再発期と寛解期とを判定する、判定方法。 Measuring the amount of peptide consisting of the amino acid sequence represented by SEQ ID NO: 1 in the blood , determining the recurrence phase and remission phase of multiple sclerosis , or recurrence of NMO (optic neuromyelitis) Judgment method to determine the period and remission period . 血液中の配列番号１で表されるアミノ酸配列からなるペプチドの量を測定することを特徴とする、多発性硬化症および/またはＮＭＯ（視神経脊髄炎）を判定する判定方法。A method for determining multiple sclerosis and / or NMO (optic neuromyelitis), comprising measuring the amount of a peptide comprising the amino acid sequence represented by SEQ ID NO: 1 in blood. 患者の血液中の配列番号１で表されるアミノ酸配列からなるペプチドの量を測定することを特徴とする、患者の多発性硬化症の再発期と寛解期とを判定する判定方法。A determination method for determining a relapsing phase and a remission phase of multiple sclerosis in a patient, which comprises measuring the amount of the peptide consisting of the amino acid sequence represented by SEQ ID NO: 1 in the blood of the patient. 患者の血液中の配列番号１で表されるアミノ酸配列からなるペプチドの量を測定することを特徴とする、患者のＮＭＯ（視神経脊髄炎）の再発期と寛解期とを判定する判定方法。A determination method for determining a relapse phase and a remission phase of NMO (optic neuromyelitis) of a patient, which comprises measuring the amount of a peptide comprising the amino acid sequence represented by SEQ ID NO: 1 in the blood of the patient. 患者の血液中の配列番号１で表されるアミノ酸配列からなるペプチドの量を追跡して測定し、高い値の場合、再発期と判定し、低い値の場合、寛解期と判定することを特徴とする、請求項７または請求項８に記載の患者の多発性硬化症の再発期と寛解期とを判定する判定方法、またはＮＭＯ（視神経脊髄炎）の再発期と寛解期とを判定する判定方法。The amount of the peptide consisting of the amino acid sequence represented by SEQ ID NO: 1 in the blood of the patient is traced and measured. If the value is high, it is determined as a relapse phase, and if it is low, it is determined as a remission phase. A determination method for determining a relapsing phase and a remission phase of multiple sclerosis in a patient according to claim 7 or 8, or a determination for determining a relapse phase and a remission phase of NMO (optic neuromyelitis) Method.
JP2008239303A 2008-09-18 2008-09-18 Method for measuring test markers for multiple sclerosis or NMO Active JP5117336B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008239303A JP5117336B2 (en) 2008-09-18 2008-09-18 Method for measuring test markers for multiple sclerosis or NMO

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008239303A JP5117336B2 (en) 2008-09-18 2008-09-18 Method for measuring test markers for multiple sclerosis or NMO

Publications (3)

Publication Number Publication Date
JP2010071789A JP2010071789A (en) 2010-04-02
JP2010071789A5 true JP2010071789A5 (en) 2011-11-04
JP5117336B2 JP5117336B2 (en) 2013-01-16

Family

ID=42203723

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008239303A Active JP5117336B2 (en) 2008-09-18 2008-09-18 Method for measuring test markers for multiple sclerosis or NMO

Country Status (1)

Country Link
JP (1) JP5117336B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2990514B1 (en) * 2012-05-14 2014-10-17 Univ Strasbourg DIFFERENTIAL DIAGNOSTIC METHOD DISCRIMINATING PLATE SCLEROSIS FROM DEVIC'S DISEASE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2543606B2 (en) * 1990-01-17 1996-10-16 帝人株式会社 How to determine multiple sclerosis
US7101679B2 (en) * 2003-11-25 2006-09-05 Mayo Foundation For Medical Education And Research Marker for neuromyelitis optica
WO2005111612A1 (en) * 2004-05-11 2005-11-24 University Of Pittsburgh Diagnosing and monitoring inflammatory diseases by measuring complement components on white blood cells
AU2007266218C1 (en) * 2006-05-26 2013-05-23 Phenomenome Discoveries Inc. Biomarkers for diagnosing multiple sclerosis, and methods thereof
JP5424331B2 (en) * 2007-10-18 2014-02-26 国立大学法人 鹿児島大学 Biomarker for liver disease diagnosis

Similar Documents

Publication Publication Date Title
JP2006225396A5 (en)
WO2008021290A9 (en) Organ-specific proteins and methods of their use
WO2007050979A3 (en) Real time nucleic acid detection in vivo using protein complementation
EP2021794B8 (en) Use of protein s100a 12 as a marker for colorectal cancer
WO2009063840A1 (en) Method and kit for measurement of endotoxin level
JP2009537798A5 (en)
ATE554389T1 (en) APEX AS A MARKER FOR LUNG CANCER
JP2010538282A5 (en)
JP2009533033A5 (en)
WO2008117067A8 (en) Protein signature/markers for the detection of adenocarcinoma
ATE388243T1 (en) DETERMINATION OF THE SEQUENCE OF A POLYNUCLEOTIDE
RU2014149089A (en) METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDE BASED ON THE APPLICATION OF EUGLOBULIN
WO2005124356A3 (en) Use of protein cbp2 as a marker for colorectal cancer
CA2510377A1 (en) Use of nicotinamide n-methyltransferase as a marker for colorectal cancer
Almasy et al. Comparative host interactomes of the SARS-CoV-2 nonstructural protein 3 and human coronavirus homologs
JP2011515672A5 (en)
WO2006053251A3 (en) Method of measuring amyloid-beta peptides
JP2009517381A5 (en)
JP2010526995A5 (en)
JP2011518338A5 (en)
ATE468535T1 (en) USE OF NNMT AS A MARKER FOR LUNG CANCER
JP2010071789A5 (en)
WO2011017656A3 (en) Non-mass determined base compositions for nucleic acid detection
CN103834747B (en) The method of the detection H1N1virus pathogenicity based on pyrophosphoric acid order-checking
WO2006089801A8 (en) Method for the redox potential-dependent detection of target molecules by interactive peptides